* Q3: EBITDA of SEK 13m and a margin of 25% * We cut EBITDA by 5-2% for '26e-'27e * Currently tradin...
* Sales -5%, adj. EBITA +25% vs. ABGSCe, 0% org. growth * '25e-'27e adj.
Redeye provides an update following Acarix’s Q3 2025 report.
RaySearch delivers incredibly strong results with record sales, a 96% gross margin, and an EBIT marg...
Redeye comments on Medivir’s Q2 report. A rights issue of cSEK150m was announced, which will fund a ...
Redeye updates on W5 post Q3-results which saw softer-than-expected topline while a strong gross mar...
Redeye updates on Xspray following its Q3 report, which featured undramatic financials but offered a...
* Sales in line, EBIT adj. EUR +0.5m vs. ABGSCe * Orders -18% vs.
Absolent’s third quarter showed sequential improvement, although sales and margins were still down Y...
Redeye comments on Fable Media’s updated full-year forecast.
Redeye return with positive estimate adjustments following GomSpace’s trading update that beat our e...
Redeye adjusts its estimates and fair value range following Arise’s Q3 report.
We lower our group gross margin assumptions by 70bp for 2025 and 20-30bp for 2026-27, predominantly ...
Kontigo Care delivered Q3 results broadly in line with our forecasts, with stable MRR and controlled...
Nettoomsättningen för det tredje kvartalet uppgick till 145,1 MSEK (113,8), motsvarande en tillväxt ...
Redeye comments briefly on the Q3 report and other recent news.
Redeye expects Smart Eye’s Q3 report, due 14 November, to show 27% y/y net sales growth and to reach...
* We trim EBIT by 4-3% on slightly lower margins * Strong growth continues, with impressive margin r...
SynAct Pharma is focused on inflammation resolution therapeutics.
* We raise our long-term EBIT estimates on better growth * Short-term margins sacrificed, but LT gro...
